We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$303M
AUM Growth
–
Cap. Flow
+$313M
Cap. Flow %
103.05%
Top 10 Hldgs %
100%
Holding
9
New
9
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$100M
2
PCVX icon
Vaxcyte
PCVX
+$82.6M
3
INZY
Inozyme Pharma
INZY
+$37.9M
4
AKUS
Akouos Inc
AKUS
+$35M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$20.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$110M 36.29%
+1,083,344
New +$100M
PCVX icon
2
Vaxcyte
PCVX
$8.81B
$59.1M 19.47%
+2,222,970
New +$82.6M
AKUS
3
DELISTED
Akouos Inc
AKUS
$35.6M 11.73%
+1,794,088
New +$35M
INZY
4
DELISTED
Inozyme Pharma
INZY
$32.8M 10.83%
+1,591,154
New +$37.9M
ALGS icon
5
Aligos Therapeutics
ALGS
$45.5M
$24.2M 7.99%
+35,062
New +$17.1M
ARQT icon
6
Arcutis Biotherapeutics
ARQT
$3.3B
$18.9M 6.23%
+671,716
New +$16.5M
FUSN
7
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$18.8M 6.19%
+1,598,379
New +$20.1M
ETTX
8
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$2.92M 0.96%
+1,180,178
New +$2.32M
ITRM
9
DELISTED
Iterum Therapeutics
ITRM
$935K 0.31%
+63,006
New +$737K

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Pivotal bioVenture Partners Investment Advisor, which disclosed 9 positions worth $303M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Karuna Therapeutics, Inc. Common Stock: 1,083,344 shares worth $110M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Pivotal bioVenture Partners Investment Advisor's largest Q4 2020 buy was Karuna Therapeutics, Inc. Common Stock: 1,083,344 shares worth $110M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 100% of its $303M portfolio in Q4 2020.
  • Pivotal bioVenture Partners Investment Advisor disclosed 9 positions in Q4 2020, its first 13F filing on record.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q4 2020, filed 9 Feb 2021.